Literature DB >> 18806632

Increased prevalence of metabolic syndrome in uncontrolled hypertension across Europe: the Global Cardiometabolic Risk Profile in Patients with hypertension disease survey.

Sverre E Kjeldsen1, Lisa Naditch-Brule, Stefano Perlini, Walter Zidek, Csaba Farsang.   

Abstract

OBJECTIVES: The Global Cardiometabolic Risk Profile in Patients with hypertension disease survey investigated the cardiometabolic risk profile in adult outpatients with hypertension in Europe according to the control of blood pressure (BP) as defined in the European Society of Hypertension and of the European Society of Cardiology (ESH/ESC) guidelines.
METHODS: Data on BP control and cardiometabolic risk factors were collected for 3370 patients with hypertension in 12 European countries. Prevalence was analyzed according to BP status and ATP III criteria for metabolic syndrome.
RESULTS: BP was controlled (BP < 140/90 mmHg for nondiabetic patients; BP < 130/80 mmHg for diabetic patients) in 28.1% of patients. Patients with uncontrolled BP had significantly higher mean weight, BMI, waist circumference, fasting blood glucose, total cholesterol and triglycerides and high-density lipoprotein cholesterol levels were significantly lower (women only) compared with patients with controlled BP (P < 0.05). The prevalence of metabolic syndrome and type 2 diabetes was also significantly higher in patients with uncontrolled BP compared with controlled BP (P < 0.001) (metabolic syndrome: 66.5 versus 35.5%; diabetes 41.1 versus 9.8%, respectively). 95.3% of patients with both metabolic syndrome and type 2 diabetes had uncontrolled BP. In a multivariate analysis, diabetes and metabolic syndrome were found to be associated with a high risk of poor BP control: odds ratio, 2.56 (metabolic syndrome); 5.16 (diabetes).
CONCLUSION: In this European study, fewer than one third of treated hypertensive patients had controlled BP. Metabolic syndrome and diabetes were important characteristics associated with poor BP control. Thus, more focus is needed on controlling hypertension in people with high cardiometabolic risk and diabetes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18806632     DOI: 10.1097/HJH.0b013e32830c45c3

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  25 in total

Review 1.  Metabolic syndrome in hypertensive patients: An unholy alliance.

Authors:  Giuseppe Mulè; Ilenia Calcaterra; Emilio Nardi; Giovanni Cerasola; Santina Cottone
Journal:  World J Cardiol       Date:  2014-09-26

2.  Modelling the costs of care of hypertension in patients with metabolic syndrome and its consequences, in Germany, Spain and Italy.

Authors:  Eberhard Wille; Jürgen Scholze; Eduardo Alegria; Claudio Ferri; Sue Langham; Warren Stevens; David Jeffries; Kerstin Uhl-Hochgraeber
Journal:  Eur J Health Econ       Date:  2010-04-20

3.  Prevalence of undiagnosed and inadequately treated type 2 diabetes mellitus, hypertension, and dyslipidemia in morbidly obese patients who present for bariatric surgery.

Authors:  Rouzbeh Mostaedi; Denise E Lackey; Sean H Adams; Stephen A Dada; Zahid A Hoda; Mohamed R Ali
Journal:  Obes Surg       Date:  2014-06       Impact factor: 4.129

4.  Epidemiological and economic burden of metabolic syndrome and its consequences in patients with hypertension in Germany, Spain and Italy; a prevalence-based model.

Authors:  Jürgen Scholze; Eduardo Alegria; Claudio Ferri; Sue Langham; Warren Stevens; David Jeffries; Kerstin Uhl-Hochgraeber
Journal:  BMC Public Health       Date:  2010-09-02       Impact factor: 3.295

Review 5.  Fixed-dose combinations as initial therapy for hypertension: a review of approved agents and a guide to patient selection.

Authors:  Bernard Waeber; François Feihl; Luis M Ruilope
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 6.  Rationale for triple-combination therapy for management of high blood pressure.

Authors:  Alan H Gradman
Journal:  J Clin Hypertens (Greenwich)       Date:  2010-08-20       Impact factor: 3.738

Review 7.  Where are we with the management of hypertension? From science to clinical practice.

Authors:  Csaba Farsang; Lisa Naditch-Brule; Angelo Avogaro; Jan Ostergren; Paolo Verdecchia; Aldo Maggioni; Philippe van de Borne; Robert Lins; Alexandre Roca-Cusachs
Journal:  J Clin Hypertens (Greenwich)       Date:  2009-02       Impact factor: 3.738

8.  Blood pressure control and components of the metabolic syndrome: the GOOD survey.

Authors:  Walter Zidek; Lisa Naditch-Brûlé; Stefano Perlini; Csaba Farsang; Sverre E Kjeldsen
Journal:  Cardiovasc Diabetol       Date:  2009-09-15       Impact factor: 9.951

9.  Effects of aerobic interval training on arterial stiffness and microvascular function in patients with metabolic syndrome.

Authors:  Ricardo Mora-Rodriguez; Miguel Ramirez-Jimenez; Valentin E Fernandez-Elias; Maria V Guio de Prada; Felix Morales-Palomo; Jesus G Pallares; Rachael K Nelson; Juan F Ortega
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-11-06       Impact factor: 3.738

10.  Effect of vitamins a, C, and e supplementation in the treatment of metabolic syndrome in albino rats.

Authors:  L S Bilbis; S A Muhammad; Y Saidu; Y Adamu
Journal:  Biochem Res Int       Date:  2012-08-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.